The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer

The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer

Released Tuesday, 13th May 2025
Good episode? Give it some love!
The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer

The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer

The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer

The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer

Tuesday, 13th May 2025
Good episode? Give it some love!
Rate Episode
List

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Exploiting Replicative Stress in Gynecological Cancers as a Therapeutic Strategy https://pubmed.ncbi.nlm.nih.gov/32571890/

Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling Into Place https://pubmed.ncbi.nlm.nih.gov/29653955/

WEE1 Inhibition in Cancer Therapy: Mechanisms, Synergies, Preclinical Insights, and Clinical Trials https://pubmed.ncbi.nlm.nih.gov/40187712/

Phase 2 Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33705205/

ADAGIO: A Phase 2b, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS5612

Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ Proc https://www.cancernetwork.com/view/azenosertib-monotherapy-yields-encouraging-responses-in-cyclin-e1-proc

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase 3 Duo-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

Homologous Recombination Deficiency: Concepts, Definitions, and Assays https://pubmed.ncbi.nlm.nih.gov/35274707/

A Replication Stress Biomarker Is Associated With Response to Gemcitabine vs Combined Gemcitabine and ATR Inhibitor Therapy in Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/34552099/

Abstract B144: Discovery and Preclinical Evaluation of Novel Oral WEE1 Degraders https://aacrjournals.org/mct/article/22/12_Supplement/B144/730300/Abstract-B144-Discovery-and-preclinical-evaluation

Show More